ProcellaRX taps Genpact alliance leader to grow partner network

ProcellaRX has named Jeanette Pascuzzi-Heacock vice president of business development and partner alliances, effective Aug. 24, 2026. The hire is meant to expand the life sciences firm's ecosystem of technology, consulting and channel partners as it pushes deeper into digital quality and validation.

Why it matters: - ProcellaRX is trying to scale its reach in regulated life sciences through partner-led growth. - The appointment adds a veteran alliance executive with experience across pharmaceutical, biotech and enterprise technology ecosystems. - The move supports ProcellaRX’s push into digital validation, Computer Software Assurance and AI-enabled systems.

What happened: - ProcellaRX named Jeanette Pascuzzi-Heacock, R.Ph., as vice president of business development and partner alliances, effective Aug. 24, 2026. - Pascuzzi-Heacock will lead new-business strategy and strategic partner and channel relationships. - The role is designed to expand how ProcellaRX delivers consulting services, technology solutions and subscription offerings to pharmaceutical, biotechnology, medical device and other regulated life sciences organizations. - ProcellaRX is based in Fairfax, Virginia.

The details: - Pascuzzi-Heacock is a registered pharmacist, ASQ Certified Six Sigma Black Belt and quality auditor. - Her background spans pharmaceutical R&D, clinical practice, product realization, quality compliance and enterprise technology at scale. - She started at Wyeth/Pfizer developing drug-device delivery systems. - Her early work included co-inventing an FDA-approved needleless syringe for NASA spaceflight missions. - She later led commercialization, healthcare provider enablement and more than 50 brand partnerships at Pfizer. - Pascuzzi-Heacock also deployed GE Healthcare’s global HCP compliance operations. - Most recently, she served as AVP, Global Alliance Partnerships at Genpact. - Her career also includes leadership roles at EPAM, UiPath and Appian. - She has managed partnerships and portfolios over $250 million. - She originated alliance arrangements that produced nine-figure, multi-year commitments in the first year. - She also delivered double-digit year-over-year growth. - At Genpact, she restored visibility to more than $100 million in unrealized partner-driven revenue. - She helped create digitized forecasting and an agentic revenue-governance framework that became a corporate standard. - Pascuzzi-Heacock holds a bachelor of science in pharmacy and an MBA in marketing from Drexel University. - Her credentials include ASQ Certified Quality Auditor and Prosci Change Practitioner. - She lives in Clayton, North Carolina, and is active in the local economic growth community. - She is also involved in efforts supporting women’s leadership in AI for healthcare and life sciences. - Dori Gonzalez-Acevedo, founder and CEO of ProcellaRX, said trust was a key factor in the hiring decision. - Gonzalez-Acevedo said Pascuzzi-Heacock understands the science, business and responsibility of the industry. - Pascuzzi-Heacock said she wants to grow the partner network that brings ProcellaRX to more customers and patients.

Between the lines: - ProcellaRX is positioning partner alliances as a core go-to-market lever, not just a support function. - The company is betting that life sciences buyers will increasingly rely on connected ecosystems of tech providers, implementation partners and quality firms. - Pascuzzi-Heacock’s mix of pharmacy, compliance and enterprise sales experience fits a market where digital tools must still clear strict validation and governance requirements.

What's next: - Pascuzzi-Heacock will develop technology and channel alliances that extend ProcellaRX’s capabilities. - She will also work to strengthen existing partner relationships and create new paths for regulated life sciences customers to access the company’s offerings. - ProcellaRX is continuing to expand its Decision Quality Intelligence practice. - The company defines Decision Quality Intelligence as creating the conditions for quality decisions to be conscious, defensible and continuous. - That framework supports ProcellaRX’s work in digital validation, CSA, quality transformation, emerging technology governance and AI-enabled systems.

The bottom line: - ProcellaRX is adding a deeply networked life sciences alliance leader to help turn its quality and digital services into a broader partner-driven business.